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ABSTRACT 
Glycogen storage disease type Ia (GSD Ia), a rare autosomal inherited disorder, is characterized 
by accumulation of excessive glycogen and fat in the liver. Primary symptoms of GSD Ia include 
hypoglycemia; metabolic acidosis; elevated levels of lactate, uric acid and lipids; hepatomagaly 
and growth retardation. Glycogen storage disease type Ia was caused by mutations in the G6PC 
gene. In this study, mutations in a Vietnamese patient with glycogen storage disease type Ia were 
analyzed using the whole exome sequencing method. A missense mutation c.356A>T 
(p.His119Leu) in the G6PC gene of the patient was identified in exon 3. Genetic analysis 
confirmed that this mutation was present under homozygous form In-silico analyses using SIFT 
and Mutation Taster confirmed the damaging effects of this mutations on the function of the 
proteins. This result enriches knowledge of the G6PC gene mutation spectrum and provides 
genetic data for further studies on glycogen storage disease type Ia in Viet Nam. 
Keywords: G6PC gene, Glycogen storage disease type Ia, mutation p.His119Leu, rare disease, 
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INTRODUCTION 
Glycogen storage disease (GSD) is a rare 
group of genetic metabolic disorders that 
affects glycogen metabolism. In patients with 
GSD, while endogenous glucose production is 
suppressed in postprandial period, exogenous 
glucose is either metabolized to pyruvate or 
stored as glycogen in the liver and skeletal 
muscle (Saltik et al., 2000; Ozen, 2007). 
Glycogen stores must be metabolized by 
enzymes before being used. In the absence of 
enzymes needed for glycogen degradation, the 
glycogen will accumulate and cause disorders. 
Glycogen storage disease affect primarily 
liverand muscles. The incidence rate of GSD I 
is approximately 1/20.000–1/43.000 live 
births (Hicks et al., 2011). 
Depending on the level of enzyme 
deficiency and the affected tissues, glycogen 
storage diseases were classified into twelve 
type (Wolfsdorf & Weinstein, 2003; Rake et 
al. 2006). Different GSD types have different 
symptoms. Most types of GSD affect liver 
(type 0, I, III, IV, VI and IX). However, some 
types of GSD have complex signs and 
symptoms, affecting muscles, liver, and heart. 
These types of GSD (except GSD type 0) can 
cause the liver to enlarge due to glycogen 
being stored in the liver instead of being 
released as glucose into blood.  Common 
symptoms of GSD are hypoglycemia, 
hyperlactatemia, hepatomegaly, 
hypertriglyceridemia. GSD type V and VII 
affect primarily the skeletal muscles, with 
muscle weakness and cramps being the most 
common symptoms. In newborns, some GSD 
types lead to death within the first year of life, 
whereas other glycogen storage diseases are 
relatively asymptomatic or may cause only 
exercise intolerance (Hicks et al., 2011). 
Glycogen storage disease type I including 
type Ia (GSD Ia) and Ib (GSD Ib) 
characterized by hepatomegaly resulting from 
accumulation of glycogen in the liver. Among 
them, GSD type Ia is more common, 
accounting for about 80% of patients with 
GSD type I with an estimated annual 
incidence rate of about 1/100,000 live births 
(Chou et al. 2002). 
Glycogen storage type Ia is an 
autosomal recessive disorder cause by 
deficiencies in the activities of glucose-6-
phosphatase (G6Pase), an integral resident 
endoplasmic reticulum (ER) protein. The 
G6PC gene is expressed primarily in the 
liver, kidneys, and intestines (Chou et al.. 
2002). Patients with GSD Ia present many 
abnormal biochemical symptoms, mainly 
fasting hypoglycemia, lactic acidosis, 
hyperlipidemia, hyperuricemia, 
hepatomegaly, and growth retardation (Gu 
et al. 2014; Karthi et al. 2019). 
The G6PC gene is located on 
chromosome 17q21.31 which is the long arm 
of chromosome 17 at position 21.31. G6Pase 
which is a glycoprotein with 357 amino acid, 
is anchored in the membrane of the ER by 9 
transmembrane helices (Pan et al.. 1998). Up 
to now, approximately 116 mutations in of the 
G6PC gene have been recorded among 550 
patients in the Human 
Gene Mutation Database (HGMD). Almost all 
previously reported variants were missense. 
The active center of G6PC is proposed to 
comprise Lys-76, Arg-83, His-119, Arg-170 
and His-176 (Stukey & Carman 1997; 
Hemrika & Wever, 1997). Mutations in active 
sites were shown to completely abolish G6PC 
enzymatic activity. 
In this study, whole exome sequencing was 
performed on a Vietnamese patient with GSD 
type Ia. A missense mutation p.His119Leu in 
G6PC gene was found in the patient and 
members of his family. Information about this 
mutation will contribute to a better 
understanding of the disease. 
MATERIALS AND METHODS 
Ethical Approval 
This study was conducted in accordance 
with the Declaration of Helsinki, and the 
protocol was approved by the Ethics 
Committee of the Institute of Genome 
Research (No. 18/QD-NCHG on 22 March, 
2018, Institute of Genome Research 
Institutional Review Board, Ha Noi, Vietnam). 
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Patient 
The patient with glycogen storage disease 
type Ia, a boy aged 7 years and 11 months, is 
the third child in the familiy whilethe second 
child died at 3 months of age due to unknown 
coma. The patient presented the first 
metabolic crisis at 3 months of age after 
immunization injection. At that time, he 
presented tachypnea, lethargy, metabolic 
acidosis (7.05),  hypoglycemia (1.9 mmol/l, 
normal: 3.3−5.5 mmol/l ), hyperlactatemia 
(9.5 mmol/l, normal: 3.3−5.5 mmol/l), 
hypertriglyceridemia (7 mmol/l, normal: 
<1,65 mmol/l), ketonuria, elevated 
transaminase (ALT: 400, normal: <40). After 
diagnosis, the patient was treated with glucose 
infusion on metabolic crisis. Over the long 
term, the patient was treated with applied diet 
therapy with soymilk, cornstarch, medium-
chain triglyceride oil and avoiding long 
fasting. He showed normal health until 6 years 
old. He was admitted to Vietnam National 
Hospital of Pediatrics because of tachypnea 
and lethargy. The patient presented 
hepatomegaly 7 cm under costal margin, 
hyperlactatemia (7.5 mmol/l), elevated 
transaminase (AST/ALT:1544/950 UI/l), 
hypertriglyceridemia (8.3 mmol/l). 
DNA extraction 
Peripheral blood samples from the patient 
and his family members were provided by 
Department of Endocrinology, Metabolism 
and Genetics, Vietnam National Hospital of 
Pediatrics. Genomic DNA was extracted from 
peripheral blood samples using QIAamp DNA 
Blood Mini Kit-QIAGEN following the 
manufacturer’s guidelines. 
Whole exome sequencing 
The DNA library of patients was prepared 
using Agilent SureSelect Target Enrichment 
kit and whole exome sequencing was 
performed by applying Illumina platform. 
Bioinformatics analysis and variants 
screening 
After sequenced by Illumina platform, 
raw data was assessed and subjected to 
quality control using FastQC. The paired-end 
reads were aligned to the reference human 
genome (GRChr37/hg19) using BWA 0.7.10 
(Li & Durbin, 2009). Picard tools 
(http://broadinstitute.gith-ub.io/picard/) was 
used to processed post-alignment data. 
Genome Analysis Toolkit v3.4 was used for 
variant calling (McKenna et al. 2010). The 
The effects of variants on genes such as 
amino acid changes were predicted using 
SnpEff v4.1 (Cingolani et al., 2012). In-silico 
analyses to confirm the effect of the 
mutations on the structure and function of the 
proteins was performed using SIFT (Ng & 
Henikoff, 2003) and Mutation Taster 
(Schwarz et al., 2014). 
The candidate variants were filtered using 
four conditions: (i) variants occurring in genes 
associated with GSD type I; (ii) all variants 
with a minor allele frequency of 0.1% were 
excluded; (iii) variants predicted as 
“Damaging” or “Disease causing” (iiii) all 
variants reported as benign in ClinVar 
database were excluded. 
Sanger sequencing to validation variants 
A fragment of G6PC gene was amplified 
using a specific primer designed using Primer 
blast (https://www.ncbi.nml.gov/tools/primer-
blast/): G6PC-2F: 5
’
-TTCCCAGAGCCTTGC 
ACAAT-3’ and G6PC-2R: 5’-AAGCCCT 
GCTGCTACTTCAC-3
’
. PCR conditions used 
for the amplification were: 95
o
C/12 min; 
(95
o
C/45 s; 64
o
C/45 s; 72
o
C/45 s) x 35 cycles 
and 72
o
C/8 min. The PCR product (639 bp) 
underwent electrophoresis in agarose 1%. 
Sanger sequencing was performed on DNA 
samples of the patient and members of his 
family for validating the variants of interest 
identified in bioinformatics analysis. 
RESULTS AND DISCUSSION 
Bioinformatics analysis revealeda 
homozygous missense variant c.356A>T 
(p.His119Leu) in  exone 3 of G6PC gene. 
This mutation involves a change from 
Histidine (His) to Leucine (Leu) at residue 
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119 (p.His119Leu). The mutation was first 
identified by Wu et al. (2000) in a Taiwan 
patient with glycogen storage disease type Ia. 
This mutation was reported in the dbSNP 
database (rs1401928680) but not in ClinVar. 
Sanger sequencing showed that the 
patient’s parents and sister carried a 
heterozygous c.356A > T mutation (Fig. 1). 
The second child of this family, who died at 3 
months of age, was not reported in this study. 
  
 
Figure 1. Analysis of p.His119Leu mutation in the patient and his family. (A) G6PC gene is 
located on chromosome 17q21.31 which is the long (q) arm of chromosome 17 at position 
21.31. (B) Exon–intron graph of G6PC gene. (C) Pedigree of the patient’s family and variant 
p.His119Leu in ther G6PC gene 
 
With a SIFT score of 0.012 (Fig. 2A) and 
MutationTaster2 result as disease-causing, 
this mutation is predicted to be deleterious. In 
addition, the His119 residue is located in a 
conserved amino acid across different species 
(Fig. 2B). 
In this study, the mutation p.His119Leu  
found in the patient changed hydrophilic 
amino acid (histidine) to hydrophobic amino 
acid (leucine). His-119 is an active site 
residue of G6Pase protein (Hemrika & 
Wever, 1997; Stukey & Carman, 1997), 
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providing the proton needed to liberate the 
glucose moiety (Chou & Mansfield, 2008). 
The mutation p.His119Leu has been 
identified in GSD-Ia patients and shown to 
completely abolish G6PC enzymatic activity 
(Shieh et al., 2002). The roles of His-119 
were confirmed by Lei et al (1995) which 
substituted this amino acid with either 
alanine (His119Ala), isoleucine (His119Ile), 
lysine (His119Lys), methionine 
(His119Met), asparagine (His119Asn), 
arginine (His119Arg) and threonine 
(His119Thr). All of the His-119 mutant have 
shown a loss of activity in G6PC catalysis. 
 
 
Figure 2. In-silico analysis of the G6PC protein. (A) The mutation was predicted to be 
“Damaging” by SIFT. (B) Conservation of the amino acid changed by p.His119Leu in G6PC 
protein mutation across different species 
 
Signs and symptoms of glycogen storage 
disease type Ia include low blood sugar 
(hypoglycemia), which can lead to seizures. 
Patient can also have a buildup of lactic acid 
in the body (lactic acidosis), high blood levels 
of uric acid (hyperuricemia), and excess 
amounts of fats in the blood (hyperlipidemia). 
Patients with GSD IA have abnormal 
enlargement of the liver (hepatomegaly), they 
may have thinning of bones (osteoporosis), 
gout, kidney disease, and high blood pressure 
in the blood vessels (Rake et al., 2002; 
Froissart et al., 2011). The patient in this 
study presented hypoglycemia, 
hyperlactatemia, hepatomegaly, and 
hypertriglyceridemia ketonuria; biochemical 
indices were abnormal. Other studies in 
Chinese and Indian patients with GSD Ia 
showed similar symptoms (Gu et al., 2014; 
Zheng et al., 2015; Karthi et al., 2019). This 
suggests that patients presented with severe 
hypoglycemia can be clearly diagnosed in 
early childhood. However, in some studies 
on mild cases without hypoglycemia and 
growth retardation, patient can be diagnosed 
in adolescence or adulthood with 
complications such as gouty arthritis, 
hepatitis or tumors called adenomas forming 
in the liver (Akanuma et al., 2000; Shieh et 
al., 2012). Therefore, the early diagnosis and 
identification by genetic analysis is very 
important for treatment. 
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Figure 3. G6Pase protein anchored in the endoplasmic reticulum (ER) by 9 transmembrane 
helices. The N terminus localized in the ER lumen and the C terminus in the cytoplasm. 
 
CONCLUSION 
In conclusion, by applying whole exome 
sequencing, we identified the p.His119Leu 
mutation in the G6PC gene in a Vietnamese 
patient with glycogen storage disease type Ia. 
This is the first report of this mutation in 
Vietnamese patients with GSD type Ia. The 
result of this study enriches knowledge of the 
G6PC gene mutation spectrum and provided 
genetic data for further studies on glycogen 
storage disease type Ia in Viet Nam. 
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